Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YM155 plus docetaxel vs docetaxel in HER2-negative metastatic breast cancer (Phase II)
2009-012439-14Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Oct 2009
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sepantronium in breast adenocarcinoma and breast cancer (2 arms), sponsored by Astellas Pharma. Primary endpoint: Progression-free survival. Started Oct 2009; status: completed.
02
Drugs
sepantronium
03
Conditions
breast adenocarcinomabreast cancer
Beyond the preview
Go deeper on 2009-012439-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012439-14.